Logo image of KHRN.CA

KHIRON LIFE SCIENCES CORP (KHRN.CA) Stock Fundamental Analysis

Canada - TSX-V:KHRN - CA49374L3065 - Common Stock

0.04 CAD
0 (0%)
Last: 5/5/2023, 7:00:00 PM
Fundamental Rating

2

Overall KHRN gets a fundamental rating of 2 out of 10. We evaluated KHRN against 34 industry peers in the Pharmaceuticals industry. KHRN may be in some trouble as it scores bad on both profitability and health. KHRN is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KHRN has reported negative net income.
KHRN had a negative operating cash flow in the past year.
KHRN.CA Yearly Net Income VS EBIT VS OCF VS FCFKHRN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M

1.2 Ratios

KHRN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KHRN.CA Yearly ROA, ROE, ROICKHRN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

1.3 Margins

KHRN's Gross Margin of 19.51% is in line compared to the rest of the industry. KHRN outperforms 47.73% of its industry peers.
KHRN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for KHRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 19.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
KHRN.CA Yearly Profit, Operating, Gross MarginsKHRN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -500 -1K -1.5K -2K

More info and screens

2

2. Health

2.1 Basic Checks

KHRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KHRN has been increased compared to 1 year ago.
Compared to 1 year ago, KHRN has a worse debt to assets ratio.
KHRN.CA Yearly Shares OutstandingKHRN.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M
KHRN.CA Yearly Total Debt VS Total AssetsKHRN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -5.28, we must say that KHRN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -5.28, KHRN is not doing good in the industry: 70.45% of the companies in the same industry are doing better.
KHRN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
KHRN has a Debt to Equity ratio of 0.05. This is in the better half of the industry: KHRN outperforms 68.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -5.28
ROIC/WACCN/A
WACC6.71%
KHRN.CA Yearly LT Debt VS Equity VS FCFKHRN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M 60M

2.3 Liquidity

KHRN has a Current Ratio of 1.91. This is a normal value and indicates that KHRN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of KHRN (1.91) is comparable to the rest of the industry.
KHRN has a Quick Ratio of 1.91. This is a bad value and indicates that KHRN is not financially healthy enough and could expect problems in meeting its short term obligations.
KHRN has a Quick ratio of 0.91. This is comparable to the rest of the industry: KHRN outperforms 43.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.91
Quick Ratio 0.91
KHRN.CA Yearly Current Assets VS Current LiabilitesKHRN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

More info and screens

7

3. Growth

3.1 Past

KHRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -59.04%.
Looking at the last year, KHRN shows a very strong growth in Revenue. The Revenue has grown by 38.20%.
KHRN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.00% yearly.
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%

3.2 Future

The Earnings Per Share is expected to grow by 25.99% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.15% on average over the next years. This is a very strong growth
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
KHRN.CA Yearly Revenue VS EstimatesKHRN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
KHRN.CA Yearly EPS VS EstimatesKHRN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KHRN. In the last year negative earnings were reported.
Also next year KHRN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KHRN.CA Price Earnings VS Forward Price EarningsKHRN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KHRN.CA Per share dataKHRN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1

4.3 Compensation for Growth

KHRN's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.88%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KHRN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KHIRON LIFE SCIENCES CORP

TSX-V:KHRN (5/5/2023, 7:00:00 PM)

0.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.47%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.19M
Analysts45.71
Price Target0.1 (150%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)0.99%
Max EPS beat(2)0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.31%
Min Revenue beat(2)-30.18%
Max Revenue beat(2)-16.44%
Revenue beat(4)1
Avg Revenue beat(4)-33.87%
Min Revenue beat(4)-93.32%
Max Revenue beat(4)4.48%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.45
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 0.36
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0.09
BVpS0.15
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 19.51%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.81%
GM growth 5YN/A
F-Score2
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 143.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.91
Quick Ratio 0.91
Altman-Z -5.28
F-Score2
WACC6.71%
ROIC/WACCN/A
Cap/Depr(3y)345.5%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-59.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.56%
EPS Next Y39.13%
EPS Next 2Y31.88%
EPS Next 3Y25.99%
EPS Next 5YN/A
Revenue 1Y (TTM)38.2%
Revenue growth 3Y143%
Revenue growth 5YN/A
Sales Q2Q%-3.82%
Revenue Next Year36.43%
Revenue Next 2Y38.09%
Revenue Next 3Y45.7%
Revenue Next 5Y40.15%
EBIT growth 1Y14.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.73%
EBIT Next 3Y30.54%
EBIT Next 5YN/A
FCF growth 1Y43.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A